Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Bayer AG's financial results show weakness, primarily due to temporary impact from its crop sciences business. Despite challenges, the company's outlook predicts continued respectable performance. Bayer's consumer health business remains strong, with potential for strong shareholder returns.

Bayer Isn't Dead

Bayer was ordered on Tuesday to pay nearly $3.5 million by a Philadelphia jury that found the company's Roundup weedkiller caused a woman's cancer, the company said, the latest in a string of trial losses for the company as it tries to fend off thousands of similar lawsuits.

Bayer ordered to pay $3.5 million in latest Roundup weedkiller trial

WHIPPANY, N.J.--(BUSINESS WIRE)--For the sixth consecutive year, Bayer U.S. received a score of 100 on the Human Rights Campaign Foundation's 2023-2024 Corporate Equality Index (CEI), the nation's foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ+ workplace equality. “For well over two decades, businesses have played an important role in furthering LGBTQ+ equality by centering employee needs and voices when it comes to workplace inclusion. While.

Bayer Earns Top Score in Human Rights Campaign Foundation's 2023-2024 Corporate Equality Index for Sixth Consecutive Year

With Bayer facing investor pressure to resolve thousands of lawsuits over its Roundup weedkiller after being hit with $2 billion in verdicts in recent weeks, all eyes are on a trial wrapping up in Philadelphia.

As Bayer confronts mounting Roundup losses, all eyes on Philadelphia trial

BERLIN & SAN DIEGO--(BUSINESS WIRE)--Bayer and CrossBay Medical Inc., today announced a development and option to license agreement that will allow the development and production of a single-handed inserter to be combined with Bayer's leading hormonal IUS portfolio. The partnership will result in the further development and expansion of CrossBay's existing innovative CrossGlide™ technology. The CrossGlide technology has the potential to substantially improve the intrauterine placement experienc.

Bayer and CrossBay Medical to develop novel Intrauterine System Inserter

SAN FRANCISCO & BASEL, Switzerland--(BUSINESS WIRE)--Hurdle, a pioneer in diagnostic testing, and the Consumer Health division of Bayer have launched a strategic partnership to advance consumer innovations in the emerging area of healthy aging. The partnership is designed to enhance the companies' shared ambition to transform self-care through personalized solutions. This alliance integrates Hurdle's cutting-edge technology with Bayer's consumer-focused product development expertise and global.

Bayer and Hurdle launch precision health strategic partnership

Bayer has made incredible strides— from traditional medications and artificial intelligence to radiology and crop science.

Bayer, One Of The Oldest Pharmaceutical Companies, Is An Innovation Powerhouse

Barclays

Charles Schwab

The market continues to rip higher in November, with the S&P 500 up 9% since Halloween. However, not all stocks are participating in the rally.

3 Battered Blue-Chip Stocks to Sell in December

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the publication of a novel health economic model in the Journal of Medical Economics, funded by Bayer, analyzing cost effectiveness and infrastructural capacity of supplemental imaging modalities for women with dense breasts at average or intermediate risk of breast cancer. The results of the model demonstrated all investigated supplemental imaging modalities — contrast-enhanced breast magnetic resonance imaging (MRI) in abbreviated (Ab-MRI.

Bayer Announces Publication of Health Economic Model Evaluation at RSNA, Providing New Insights Into Cost Effectiveness and Capacity Needs of Supplemental Screening Modalities for Dense Breasts

Bayer held a call with investors on Monday after a raft of bad news led some of them to question whether the German group had been upfront about its prospects ahead of a $5.75 billion bond issuance, three sources familiar with the situation said on Wednesday.

Exclusive: Bayer holds call with bond investors after raft of bad news

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline for an investigational contrast agent as well as new innovations in the area of Artificial Intelligence (AI). The company announced that new clinical data for gadoquatrane, Bayer's investigative macrocyclic gadolinium-based compound currently in Phase III development, will be presented at the 2023 Radiological Society of North America (RSNA) Annual Meeting.

Bayer Championing Advancements in Radiology Pipeline and Accelerating AI Innovation

Bayer's (BAYRY) phase III cardiovascular drug study is stopped due to low efficacy compared with Eliquis. The company suffers another setback in Roundup Litigation.

Bayer (BAYRY) Stops Heart Drug Study Due to Lack of Efficacy

Bayer was ordered to pay $1.56 billion to four plaintiffs after a Missouri judge ruled that the company's Roundup weedkiller caused cancer. A Cole County, Mo.

Bayer to pay $1.56B in latest loss over cancer-causing Roundup weedkiller

Bayer AG (ETR:BAYN, OTC:BAYZF), the German pharmaceutical giant, has seen its shares tank more than 20% to a near 18-year low following the failure of a key drug trial and legal challenges in the United States. The company's experimental anticoagulant, asundexian, proved less effective than existing treatments in a critical phase III trial, leading to the termination of the study.

Bayer shares plunge to a near two-decade low after blood thinner trial failure

Bayer lost a fifth of its market value at one point Monday, after the German pharmaceutical and agricultural group said it had ended a late-stage test for the anti-thrombotic drug asundexian due to a lack of efficacy.

Bayer shares plunge by more than 20% after trial of potential blockbuster drug halted

Bayer says late-stage testing of a drug called asundexian used to treat heart disease would be stopped because it didn't appear to be effective.

Bayer Stock Drops to Lowest Since 2009 as Blood Thinner Trial Fails

Germany's Bayer AG said on Sunday it is cancelling a phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor.

Bayer cancels asundexian phase III study program

A Missouri jury ordered Bayer to pay $1.56 billion to four plaintiffs who claimed the company's Roundup weedkiller caused injuries including cancer, a verdict that could intensify investor pressure on the German drugs and agricultural chemicals company to change its legal strategy.

Bayer ordered to pay $1.56 billion in latest US trial loss over Roundup weedkiller

DALLAS--(BUSINESS WIRE)-- #Bayer--Forrest Weldon Law Group delivered justice to victims poisoned by Bayer's Roundup weedkiller, with a jury Friday awarding $1.56 billion to plaintiffs.

Forrest Weldon Law Group Delivers Justice With $1.56 Billion Victory in Bayer Roundup Trial

A Missouri jury found in favor of plaintiffs as verdicts seesaw in trials involving the fertilizer.

Bayer Told to Pay $1.56 Billion After Losing Roundup Case

Bayer said on Friday it was voluntarily recalling one lot of its cancer drug Vitrakvi due to the presence of microbial contamination.

Bayer recalls one lot of cancer drug Vitrakvi

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer is voluntarily recalling one lot of Vitrakvi® (larotrectinib) Oral Solution 20 mg/mL in 100mL glass bottles to the consumer/user level. The product is being recalled due to microbial contamination identified as Penicillium brevicompactum observed during routine ongoing stability testing. Risk Statement: Given that Vitrakvi® is indicated for the treatment of solid tumors that are NTRK gene fusion positive, it is expected that patients on Vitrakvi® may be im.

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer on Monday said it would voluntarily withdraw the follicular lymphoma drug Aliqopa, also known as copanlisib, from the U.S. market after a trial designed to confirm its benefit did not show the desired effect on overall survival.

Bayer withdraws follicular lymphoma drug after further trial fails

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that, following discussions with the U.S. Food and Drug Administration (FDA), it will work with the FDA on a voluntary withdrawal of the Aliqopa® (copanlisib) U.S. New Drug Application for adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. Aliqopa® was granted accelerated approval by the FDA in September 2017 based on CHRONOS-1, an open-label, single-arm Phase II study. The FDA req.

Bayer Provides Update on Aliqopa® (copanlisib)

Bayer said on Friday that the European Medicines Agency recommended approval of a higher dose version of eye drug Eylea for treatment of a leading cause of blindness among the elderly, stepping up competition with Roche.

News for Bayer AG Stock (BAYRY)